Correction: Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis (Antimicrobial Agents and Chemotherapy (2014) 58:11 (6962–6965) DOI: 10.1128/AAC.03486-14);Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6962-6965

  Arora, Kriti ^a   Ochoa Montaño, Bernardo ^b   Tsang, Patricia S ^a   Blundell, Tom L ^b   Dawes, Stephanie S ^c   Mizrahi, Valerie ^c,d   Bayliss, Tracy ^e   Mackenzie, Claire J ^e   Cleghorn, Laura A T ^e   Ray, Peter C ^e   Wyatt, Paul G ^e   Uh, Eugene ^a   Lee, Jinwoo ^a   Barry, Clifton E ^a   Boshoff, Helena I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; MOLECULAR SCAFFOLD; STIGMATELLIN; IMIDAZO(1,2-A)PYRIDINE; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RESAZURIN; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; ENERGY METABOLISM; ENZYME INHIBITION; GENE MUTATION; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRIAL RESPIRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; ELECTRON TRANSPORT; ENZYMOLOGY; GENE INACTIVATION; GENETICS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROTEIN TERTIARY STRUCTURE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BINDING SITES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; GENE KNOCKOUT TECHNIQUES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; TUBERCULOSIS; XANTHENES;

EID: 84908276113     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01429-17     Document Type: Erratum

References (19)

1. Mahajan R. 2013. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int. J. Appl. Basic Med. Res. 3:1-2. http://dx.doi.org/10.4103/2229-516X.112228.
2. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
3. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19:1157-1160. http://dx.doi.org/10.1038/nm.3262.
4. Moraski GC, Markley LD, Hipskind PA, Boshoff H, Cho S, Franzblau SG, Miller MJ. 2011. Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med. Chem. Lett. 2:466-470. http://dx.doi.org/10.1021/ml200036r.
5. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernandez R, Alemparte C, Remuinan MJ, Barros D, Ballell L, Besra GS. 2012. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7:e52951. http://dx.doi.org/10.1371/journal.pone.0052951.
6. Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supek F, Glynne R, Zheng J, Boshoff HI, Barry CE, III, Dick T, Pethe K, Camacho LR. 2012. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7:1190-1197. http://dx.doi.org/10.1021/cb2004884.
7. Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, Hwang CH, Boshoff H, Miller MJ. 2012. Generation and exploration of new classes of antitubercular agents: the optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorg. Med. Chem. 20:2214-2220. http://dx.doi.org/10.1016/j.bmc.2012.02.025.
8. Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ. 2013. Advancement of imidazo[1,2-a]pyridines with improved pharmacokinetics and nanomolar activity against Mycobacterium tuberculosis. ACS Med. Chem. Lett. 4:675-679. http://dx.doi.org/10.1021/ml400088y.
9. Esser L, Quinn B, Li YF, Zhang M, Elberry M, Yu L, Yu CA, Xia D. 2004. Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc(1) complex. J. Mol. Biol. 341:281-302. http://dx.doi.org/10.1016/j.jmb.2004.05.065.
10. Khoje AD, Charnock C, Wan B, Franzblau S, Gundersen LL. 2011. Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles. Bioorg. Med. Chem. 19:3483-3491. http://dx.doi.org/10.1016/j.bmc.2011.04.023.
11. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. 2007. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97:539-547. http://dx.doi.org/10.1093/toxsci/kfm052.
12. Hill JR, Deane CM. 2013. MP-T: improving membrane protein alignment for structure prediction. Bioinformatics 29:54-61. http://dx.doi.org/10.1093/bioinformatics/bts640.
13. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815. http://dx.doi.org/10.1006/jmbi.1993.1626.
14. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. 2003. Improved protein-ligand docking using GOLD. Proteins 52:609-623. http://dx.doi.org/10.1002/prot.10465.
15. Goldman RC. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis 93:569-588. http://dx.doi.org/10.1016/j.tube.2013.09.003.
16. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105:11945-11950. http://dx.doi.org/10.1073/pnas.0711697105.
17. Domenech P, Rog A, Moolji JU, Radomski N, Fallow A, Leon-Solis L, Bowes J, Behr MA, Reed MB. 2014. Origins of a 350-kilobase genomic duplication in Mycobacterium tuberculosis and its impact on virulence. Infect. Immun. 82:2902-2912. http://dx.doi.org/10.1128/IAI.01791-14.
18. 3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. J. Bacteriol. 187:6300-6308. http://dx.doi.org/10.1128/JB.187.18.6300-6308.2005.
19. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE, III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279:40174-40184. http://dx.doi.org/10.1074/jbc.M406796200.